Skip to main content
. 2017 Feb 13;101(6):782–790. doi: 10.1002/cpt.620

Figure 3.

Figure 3

Mean ( ± standard deviation) plasma concentrations of isavuconazole (a) and moxifloxacin (b) following the Day 13 dose in the phase I clinical study.